CN1353003A - 自植物萃取物中筛选活性成份的新颖方法 - Google Patents
自植物萃取物中筛选活性成份的新颖方法 Download PDFInfo
- Publication number
- CN1353003A CN1353003A CN01132691A CN01132691A CN1353003A CN 1353003 A CN1353003 A CN 1353003A CN 01132691 A CN01132691 A CN 01132691A CN 01132691 A CN01132691 A CN 01132691A CN 1353003 A CN1353003 A CN 1353003A
- Authority
- CN
- China
- Prior art keywords
- plant
- biological activity
- extract
- activity
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 36
- 238000012216 screening Methods 0.000 title claims abstract description 10
- 239000000419 plant extract Substances 0.000 title claims abstract description 5
- 230000008569 process Effects 0.000 title abstract description 4
- 239000000523 sample Substances 0.000 claims abstract description 27
- 239000007787 solid Substances 0.000 claims abstract description 27
- 239000000284 extract Substances 0.000 claims abstract description 25
- 102000006240 membrane receptors Human genes 0.000 claims abstract description 6
- 108020004084 membrane receptors Proteins 0.000 claims abstract description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 23
- 102000004169 proteins and genes Human genes 0.000 claims description 23
- 230000004071 biological effect Effects 0.000 claims description 19
- 238000002372 labelling Methods 0.000 claims description 16
- 230000000694 effects Effects 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 12
- 239000003146 anticoagulant agent Substances 0.000 claims description 11
- 238000009396 hybridization Methods 0.000 claims description 8
- 230000002785 anti-thrombosis Effects 0.000 claims description 7
- 238000001727 in vivo Methods 0.000 claims description 7
- 241000628997 Flos Species 0.000 claims description 6
- 229940127219 anticoagulant drug Drugs 0.000 claims description 6
- 238000001514 detection method Methods 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 102000003886 Glycoproteins Human genes 0.000 claims 2
- 108090000288 Glycoproteins Proteins 0.000 claims 2
- 238000011010 flushing procedure Methods 0.000 claims 1
- 238000007689 inspection Methods 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 37
- 230000000975 bioactive effect Effects 0.000 abstract description 7
- 244000020518 Carthamus tinctorius Species 0.000 abstract description 5
- 235000003255 Carthamus tinctorius Nutrition 0.000 abstract description 5
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 abstract 1
- 241000405070 Percophidae Species 0.000 abstract 1
- 238000012258 culturing Methods 0.000 abstract 1
- 238000010586 diagram Methods 0.000 description 21
- 238000005516 engineering process Methods 0.000 description 20
- 241000196324 Embryophyta Species 0.000 description 19
- 239000007788 liquid Substances 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 10
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 208000007536 Thrombosis Diseases 0.000 description 6
- 150000007523 nucleic acids Chemical group 0.000 description 6
- 239000000902 placebo Substances 0.000 description 6
- 229940068196 placebo Drugs 0.000 description 6
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 6
- 229920002554 vinyl polymer Polymers 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 210000001758 mesenteric vein Anatomy 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 210000003462 vein Anatomy 0.000 description 5
- 230000009471 action Effects 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 230000002650 habitual effect Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012676 herbal extract Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000000713 mesentery Anatomy 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- WRLGYAWRGXKSKG-UHFFFAOYSA-M phenobarbital sodium Chemical compound [Na+].C=1C=CC=CC=1C1(CC)C(=O)NC([O-])=NC1=O WRLGYAWRGXKSKG-UHFFFAOYSA-M 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- LLIANSAISVOLHR-GBCQHVBFSA-N 5-[(3as,4s,6ar)-2-oxidanylidene-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoic acid Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21.N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 LLIANSAISVOLHR-GBCQHVBFSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- 206010058990 Venous occlusion Diseases 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000002406 microsurgery Methods 0.000 description 1
- 238000002663 nebulization Methods 0.000 description 1
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 1
- 238000007500 overflow downdraw method Methods 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960002511 phenobarbital sodium Drugs 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- -1 phosphate ester Chemical class 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (16)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70830600A | 2000-11-07 | 2000-11-07 | |
US09/708,306 | 2000-11-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1353003A true CN1353003A (zh) | 2002-06-12 |
CN1220060C CN1220060C (zh) | 2005-09-21 |
Family
ID=24845266
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN01120742A Pending CN1352945A (zh) | 2000-11-07 | 2001-05-28 | 充作抗血栓形成剂的腺苷 |
CNB011326913A Expired - Fee Related CN1220060C (zh) | 2000-11-07 | 2001-09-04 | 自植物萃取物中筛选活性成份的方法及组套 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN01120742A Pending CN1352945A (zh) | 2000-11-07 | 2001-05-28 | 充作抗血栓形成剂的腺苷 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20020082241A1 (zh) |
EP (2) | EP1205754B1 (zh) |
CN (2) | CN1352945A (zh) |
AT (2) | ATE299593T1 (zh) |
AU (1) | AU5178801A (zh) |
CA (1) | CA2348845A1 (zh) |
DE (2) | DE60111906D1 (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6855343B2 (en) * | 2002-05-21 | 2005-02-15 | Advanced Gene Technology, Corp | Method to ascertain the quality of herbs |
CN106501415A (zh) * | 2016-12-02 | 2017-03-15 | 丽珠集团丽珠制药厂 | 一种阿魏酸钠、阿司匹林、桂利嗪和维生素b1的含量测定方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5770198A (en) * | 1988-05-18 | 1998-06-23 | The Research Foundation Of The State Of New York | Platelet-specific chimeric 7E3 immunoglobulin |
CA2073696A1 (en) * | 1990-02-02 | 1991-08-03 | Peter L. Barker | Cyclic peptides containing arg-gly-asp flanked by proline |
US5677290A (en) * | 1990-05-10 | 1997-10-14 | Fukunaga; Atsuo F. | Therapeutic use of adenosine compounds as surgical anesthetics |
JP3002903B2 (ja) * | 1991-04-09 | 2000-01-24 | 第一化学薬品株式会社 | 血管外血液の抗凝固・抗血小板剤組成物及びこれを用いる血小板活性化の分子マーカーの測定法 |
US6137002A (en) * | 1993-07-22 | 2000-10-24 | Eli Lilly And Company | Glycoprotein IIb/IIIa antagonists |
IL121272A (en) * | 1997-07-10 | 2000-06-01 | Can Fite Technologies Ltd | Pharmaceutical compositions comprising adenosine and their use for treating or preventing leukopenia |
DE19802576B4 (de) * | 1998-01-23 | 2004-10-28 | Xerion Pharmaceuticals Ag | Verfahren zur gleichzeitigen Identifizierung von Proteinen und ihren Bindungspartnern |
US6713309B1 (en) * | 1999-07-30 | 2004-03-30 | Large Scale Proteomics Corporation | Microarrays and their manufacture |
-
2001
- 2001-05-03 DE DE60111906T patent/DE60111906D1/de not_active Expired - Lifetime
- 2001-05-03 EP EP01110765A patent/EP1205754B1/en not_active Expired - Lifetime
- 2001-05-03 AT AT01110765T patent/ATE299593T1/de not_active IP Right Cessation
- 2001-05-10 US US09/853,524 patent/US20020082241A1/en not_active Abandoned
- 2001-05-25 CA CA002348845A patent/CA2348845A1/en not_active Abandoned
- 2001-05-28 CN CN01120742A patent/CN1352945A/zh active Pending
- 2001-05-29 EP EP01112092A patent/EP1205182B1/en not_active Expired - Lifetime
- 2001-05-29 DE DE60111905T patent/DE60111905D1/de not_active Expired - Lifetime
- 2001-05-29 AT AT01112092T patent/ATE299374T1/de not_active IP Right Cessation
- 2001-06-06 AU AU51788/01A patent/AU5178801A/en not_active Abandoned
- 2001-09-04 CN CNB011326913A patent/CN1220060C/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
AU5178801A (en) | 2002-05-09 |
EP1205754B1 (en) | 2005-07-13 |
US20020082241A1 (en) | 2002-06-27 |
EP1205182A3 (en) | 2002-09-04 |
CN1220060C (zh) | 2005-09-21 |
EP1205754A3 (en) | 2002-07-17 |
EP1205182B1 (en) | 2005-07-13 |
CA2348845A1 (en) | 2002-05-07 |
ATE299374T1 (de) | 2005-07-15 |
DE60111905D1 (de) | 2005-08-18 |
ATE299593T1 (de) | 2005-07-15 |
EP1205182A2 (en) | 2002-05-15 |
CN1352945A (zh) | 2002-06-12 |
DE60111906D1 (de) | 2005-08-18 |
EP1205754A2 (en) | 2002-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6436640B1 (en) | Use of LNA in mass spectrometry | |
Qin et al. | Optimization of selenylation conditions for Chinese angelica polysaccharide based on immune-enhancing activity | |
CN101716283A (zh) | 铁皮石斛多糖指纹图谱的构建方法 | |
CN101957345A (zh) | 一种美洲大蠊提取物中活性成份的检测方法 | |
TW200521139A (en) | Biomakers for liver diseases and method for using same | |
WO2021047394A1 (zh) | 一种分子网络化分析地骨皮化合物结构的方法 | |
CN1244702C (zh) | 一种鞘氨醇杆菌及用其生产的肝素酶生产肝素寡糖的方法 | |
CN102172518B (zh) | 一种新型手性色谱柱固定相及其制备方法 | |
CN1844116A (zh) | 乌饭树黑色素中黄酮类单体的提取、分离、纯化及鉴定 | |
CN101974007B (zh) | 一种从中药材鬼灯檠中提取岩白菜素的方法 | |
CN106706829A (zh) | 免疫亲和净化‑液相色谱串联质谱测定贝类中腹泻性贝类毒素的方法 | |
CN103602658A (zh) | 一种新型靶向核酸分子的捕获与富集技术 | |
CN1693890A (zh) | 同时测定食品中残留的多种有机磷的gc/ms内标检测方法 | |
CN101832996B (zh) | 一种中药生物芯片的基片及其制备方法和用途 | |
CN1220060C (zh) | 自植物萃取物中筛选活性成份的方法及组套 | |
Zhang et al. | A collection of transcriptomic and proteomic datasets from sesame in response to salt stress | |
CN108623699A (zh) | 瓜蒌皮多糖glp-5-1、其制备方法及用途 | |
CN104764847A (zh) | 含n-乙酰化结构肝素寡糖的制备方法 | |
CN114428130B (zh) | 一种核桃青皮多酚提取物降脂的潜在标志物及代谢通路的获得方法 | |
Meissen et al. | Differentiation of 3-O-sulfated heparin disaccharide isomers: identification of structural aspects of the heparin CCL2 binding motif | |
CN107192778B (zh) | 一种基于靶蛋白亲和整体色谱柱分离细菌生物膜抑制成分的方法 | |
Lee et al. | A serological and disc electrophoretic study of North American Typha | |
JP2004191368A (ja) | ターゲット分子の検出方法 | |
CN1314964C (zh) | 一种用指纹图谱控制板蓝根及其制剂质量和药效的方法 | |
CN110028531B (zh) | 一种从土壤中提取分离黄酮类物质的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: YU ZHEN Free format text: FORMER OWNER: XIANJIN GENE CO LTD Effective date: 20061208 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20061208 Address after: Taiwan province Taipei County Sijhih Fude road 159 Lane 2, 4 floor Patentee after: Yu Zhen Address before: No. seven, No. 2-1, industrial zone, Taichung City, Taiwan Patentee before: Xianjin Gene Co., Ltd. |
|
ASS | Succession or assignment of patent right |
Owner name: SHANGHE PHARMACEUTICAL CO.LTD., BRITISH VIRGIN IS Free format text: FORMER OWNER: YU ZHEN Effective date: 20071228 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20071228 Address after: The British Virgin Islands of Tortola Rhodes town new thousand Baez.. Patentee after: British Virgin Islands Shang Ya pharmaceutical Limited by Share Ltd Address before: Taiwan province Taipei County Sijhih Fude road 159 Lane 2, 4 floor Patentee before: Yu Zhen |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20090306 Address after: No. 222, No. 2 West Ring Road, Kunming hi tech Development Zone, Yunnan Patentee after: Yunnan Baiyao Chinese Herbal Medicament Chip Co., Ltd. Address before: The British Virgin Islands of Tortola Rhodes town new thousand Baez.. Patentee before: British Virgin Islands Shang Ya pharmaceutical Limited by Share Ltd |
|
ASS | Succession or assignment of patent right |
Owner name: YUNNAN PROV BAIYAO CHINESE MEDICINAL HERB CHIP CO. Free format text: FORMER OWNER: SHANGHE PHARMACEUTICAL CO.LTD., BRITISH VIRGIN ISLANDS Effective date: 20090306 |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050921 Termination date: 20200904 |
|
CF01 | Termination of patent right due to non-payment of annual fee |